



**AALBORG UNIVERSITY**  
DENMARK

**Aalborg Universitet**

## **Topical timolol in dermatology**

*infantile haemangiomas and beyond*

Alzaid, M.; Al-Naseem, A.; Al-Niaimi, F.; Ali, F. R.

*Published in:*  
Clinical and Experimental Dermatology

*DOI (link to publication from Publisher):*  
[10.1111/ced.15021](https://doi.org/10.1111/ced.15021)

*Publication date:*  
2022

*Document Version*  
Accepted author manuscript, peer reviewed version

[Link to publication from Aalborg University](#)

*Citation for published version (APA):*  
Alzaid, M., Al-Naseem, A., Al-Niaimi, F., & Ali, F. R. (2022). Topical timolol in dermatology: infantile haemangiomas and beyond. *Clinical and Experimental Dermatology*, 47(5), 819-832. Advance online publication. <https://doi.org/10.1111/ced.15021>

### **General rights**

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal -

### **Take down policy**

If you believe that this document breaches copyright please contact us at [vbn@aub.aau.dk](mailto:vbn@aub.aau.dk) providing details, and we will remove access to the work immediately and investigate your claim.

DR FAISAL REHMAN ALI (Orcid ID : 0000-0002-8588-791X)

Article type : Review Article

## **Topical timolol in dermatology: infantile hemangiomas and beyond**

**Running head:** Timolol in dermatology

M. Alzaid,<sup>1\*</sup> A. Al-Naseem,<sup>1\*</sup> F. Al-Niaimi<sup>2</sup> and F.R. Ali<sup>3,4</sup>

<sup>1</sup>University of Manchester Medical School, Manchester, UK

<sup>2</sup>Department of Dermatology, Aalborg University Hospital, Aalborg, Denmark.

<sup>3</sup>Mid Cheshire NHS Foundation Trust, Macclesfield, UK

<sup>4</sup>Dermatological Surgery & Laser Unit, St John's Institute of Dermatology, Guy's Hospital Cancer Centre, Guy's and St Thomas' NHS Foundation Trust, Great Maze Pond, London, UK

\*Co-first author: MZ and AN contributed to this work equally

**Corresponding author:** Dr Faisal R. Ali.

**Email:** f.r.ali.01@cantab.net.

**Conflicts of interest:** none

**Funding statement:** The authors received no financial support for research, authorship and/or publication of this review article.

**Data availability statement:** Data sharing not applicable to this article as no datasets were generated or analysed during the current study.

### **What's already known about this topic?**

- Timolol is a non-selective beta-blocker widely used for treatment of glaucoma
- Systemic beta-blockers (propranolol) have revolutionised treatment of infantile haemangiomas
- Topical timolol is of theoretical benefit for a range of dermatological conditions

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1111/CED.15021](https://doi.org/10.1111/CED.15021)

This article is protected by copyright. All rights reserved

### **What does this study add?**

- Off-license dermatological indications for topical timolol include infantile haemangiomas, Kaposi's sarcoma, ulceration, promotion of wound healing, acne and rosacea
- Topical timolol for dermatological indications appears to be safe (to date) with reported adverse reactions mostly been localised in nature
- Larger studies are needed to corroborate safety data and efficacy compared to conventional treatments

### **Learning points**

1. Timolol is a non-selective beta blocker, used in dermatology for its vasoconstrictive, angiogenesis blockade and wound healing properties.
2. Timolol has been used for infantile haemangiomas treatment widely, and now interest has resurged as less invasive, low-cost and simple treatment particularly in PG, KS, chronic wound healing, post-surgical wounds, acne, rosacea, eczema, red scrotum syndrome, heel fissures, post-traumatic reactive angioendotheliomatosis and tufted angioma.
3. Timolol has a low adverse effect profile, with few incidences of systemic absorption, especially when mucous membranes and ulcerated area are avoided.
4. Timolol hydrogel 0.1% has shown less systematic absorption potential, with the same efficacy compared to 0.5% timolol aqueous solution.

## **Abstract**

Timolol, a non-selective  $\beta$ -adrenergic receptor blocker, is well-tolerated and is becoming increasingly popular in dermatology especially after its use in the management of infantile hemangiomas. Its effects are mainly due to vasoconstriction, inhibition of angiogenesis and keratinocyte migration promotion for re-epithelialization and wound healing. We review the evidence behind the use of timolol in several dermatological conditions including infantile hemangiomas, pyogenic granulomas, Kaposi's sarcoma, chronic wound healing, post-surgical wounds, acne vulgaris, rosacea, eczema and red scrotum syndrome.

## **Introduction/Background**

$\beta$ -adrenergic receptor blockers are commonly used systemically in the management of many cardiovascular diseases and more recently recognized for treatment of infantile haemangiomas. We review the evidence supporting the use of topical timolol, a non-selective beta-adrenergic receptor antagonist, for an array of dermatological indications.

## **Mechanism of action**

Timolol is a non-selective beta-adrenergic receptor antagonist of moderate lipid solubility, widely used for glaucoma management. Timolol decreases the sympathetic stimulation of  $\beta$  receptors by competing with catecholamines. Blockade of vascular  $\beta$ -adrenergic receptors, inhibits tumour proliferation and angiogenesis via down-regulating vascular endothelial growth factor. Furthermore, it enhances keratinocyte migration by reducing phosphatase 2A phosphorylation and increases the cellular migration to the negatively charged centre of the injured wound.<sup>1</sup>

## **Infantile hemangiomas**

Topical timolol has been used as a less invasive alternative to systemic propranolol for infantile haemangiomas (IH). A meta-analysis (887 patients from 10 studies, 0.5% timolol used in 90% studies) showed significantly improved response rate when compared to the controls ( $p < 0.00001$ ) during treatments of two to six months duration (Table 1).<sup>2</sup> Topical timolol has been proposed as first line treatment for deep lesions and functionally compromised patients.<sup>3</sup> Five children experiencing purely deep lesions and amblyogenic features showed complete regression after using topical timolol maleate 0.5% solution, three drops twice daily for mean duration 10 months.<sup>4</sup> Low concentration timolol gel (0.1%) five times daily; resulted in mean improvement in global assessment score of 2.56 (range 1.67-3) noticed in all 25 children with IH (mean age 30 weeks, range 12-68 weeks).<sup>5</sup>



### **Pyogenic granuloma**

Timolol has been used as a topical alternative to procedural interventions for pyogenic granulomas (PGs). Amongst 17 patients with ocular PGs (mean age 23 years; range 3-67 years), 88% demonstrated complete lesion resolution with 0.5% timolol solution given twice daily for a period between two to five weeks with no recurrences noted after mean 9.47 months. Two patients needed surgical excision after 6 weeks of no response.<sup>6</sup> A separate case series suggested that efficacy of timolol is variable after two thirds of patients required electrosurgery as a result of partial (2/10 cases) or no (4/10 cases) response. Efficacy of timolol was proposed to be better in PGs of recent onset and higher vascularity.<sup>7</sup>

### **Kaposi's sarcoma**

Where tumours are localised, topical timolol has been used as a treatment for Kaposi's sarcoma (KS) due to its anti-angiogenic properties and possible lysis of viral-infected cells. Most of the published data illustrated partial to complete resolution when administering 0.5% or 0.1% timolol strength in HIV negative patients.<sup>8</sup> In the two cases of HIV negative KS patients treated with 0.5% timolol solution twice daily for a twelve-week period, lesions showed significant improvement after 6 and 12 weeks with no recurrences after 20 months.<sup>9</sup> A HIV positive KS patient, 0.1% timolol gel applied twice daily induced resolution within 6 weeks with no recurrence after four months.<sup>10</sup>

### **Chronic recalcitrant wound healing**

Topical timolol facilitates wound healing through the promotion of keratinocyte migration. Thirty nine patients with 55 chronic wounds of various aetiologies (including venous insufficiency, vasculitis, pressure sores, trauma) recalcitrant to conventional treatments were treated with topical timolol 0.5% every dressing change (frequency from twice daily to alternate days). Notably, 34/55 wounds had completely healed with 89.5 days median treatment duration and only 6/55 showed no improvement in 76 median treatment duration days. Optimal healing was proposed to be achieved with compression and more frequent application of timolol.<sup>11</sup> A case-control study with 60 patients with chronic diabetic and venous ulcers showed the timolol group had an increased percentage improvement in the ulcer area.<sup>12</sup> Two children with junctional epidermolysis bullosa with chronic wounds of the neck fold and nailbed were treated successfully with topical timolol.<sup>13</sup>

### **Post-surgical wounds**

Topical timolol promotes reepithelisation of iatrogenic wounds. Following successful use in two patients, Waldman *et al.* suggested 0.5% timolol ophthalmic gel forming solution be used twice daily until complete resolution as a second line treatment for wounds refractory to standard therapy. A patient with hypergranulation refractory to daily nonadherent gauze dressings and both oral and topical antibiotics for several months, showed complete settling of hypergranulation and surgical site re-epithelialization after nine days.<sup>14</sup> A randomized control trial (RCT) of six patients with acute surgical scars showed patients applying topical timolol group had higher visual analogues scores (VAS) and enhanced cosmesis compared to application of saline control (mean VAS: timolol 6.5 versus control 2.5;  $p < 0.05$ ).<sup>15</sup> Topical timolol has been reported to be helpful for patients with surgical defects following Mohs surgery<sup>16</sup> and a patient with a slowly healing wound following radiotherapy.

A lady with a refractory chronic mid-back wound due to thoractomy for previous cardiac surgery was treated with 0.5% timolol drops three to four drops daily with complete epithelilaization seen in eight weeks.<sup>17</sup> Topical timolol has proved to be useful in restoring skin-barrier function following fractional CO2 laser therapy for acne.<sup>18</sup>

### **Acne vulgaris and rosacea**

Timolol through its  $\beta$ -blocking properties both suppresses inflammatory mediators and induces vasoconstriction which can be helpful in reducing disease severity and erythema in chronic inflammatory skin diseases such as acne and rosacea.<sup>19</sup>

Reduction in erythematotelangectatic rosacea was seen in an 8-patient trial; however at 16 weeks erythema recurred.<sup>20</sup> A case-study looking at post-acne erythema and hyperpigmentation showed improvement with topical timolol on subjective dermoscopic evaluation following three months of therapy.<sup>21</sup>

### **Miscellaneous**

A patient with recalcitrant fissures and erosions caused by eczema showed complete healing one week following application of topical timolol on.<sup>22</sup>

A patient with red scrotum syndrome resistant to other treatments showed response within two weeks after using topical timolol.<sup>23</sup> Timolol 0.5% ophthalmic solution has shown symptom relief and significant healing of painful and deep heel fissures after two weeks of therapy.<sup>24</sup> A patient with post-traumatic reactive angioendotheliomatosis (PRA) used timolol maleate 0.5% ophthalmic solution and demonstrated a full resolution for all lesions with mild scarring after six weeks.<sup>25</sup> Four

months of 0.5% timolol gel-forming solution for a four-month-old child with tufted angioma resulted in almost complete resolution.<sup>26</sup>

### **Adverse effects and safety profile**

Topical timolol is generally well tolerated with few adverse events (Es); systemic absorption could occur particularly if applied to mucous membranes and ulcerated areas. Timolol applied as eye drops could enter the nasolacrimal duct and reach the nasal mucosa, leading to 80% systemic absorption and the avoidance of first pass metabolism. As a non-selective beta blocker, timolol could theoretically cause bradycardia, hypotension, bronchospasm induction, fatigue, hyperglycaemia, AV block, syncope, worsening congestive heart failure and sleep disturbance.<sup>27,28</sup>

Timolol hydrogel 0.1% may be associated with fewer systemic AEs compared to 0.5% timolol aqueous solution with comparable efficacy. Lin et al. conducted a meta-analysis involving 2098 patients and concluded that topical timolol is associated with low incidence of AEs, and most of them are classed as localized including, desquamation and erythema.<sup>29</sup> Several cases of allergic contact dermatitis have been reported in the literature after the application of topical timolol.<sup>30</sup> One child out of sixty experienced insomnia and shortness of breath upon using 0.5% topical timolol maleate solution twice daily.<sup>31</sup>

### **Conclusion**

Topical timolol is a low-cost, effective and simple treatment with few AEs reported in dermatology patients. Larger RCTs and rigorous meta-analyses are needed to establish the optimal concentrations and frequency of application and confirm the safety profile of this off-licence medication. Dermatologists should consider use of topical timolol, in patients with haemangiomas and PGs where surgical therapy is undesirable and recalcitrant chronic and surgical wounds.

### **References**

- 1 Chen L, Tsai TF. The role of beta-blockers in dermatological treatment: a review. *J Eur Acad Dermatol Venereol* 2018; **32**: 363-71.
- 2 Zheng L, Li Y. Effect of topical timolol on response rate and adverse events in infantile hemangioma: a meta-analysis. *Archives of Dermatological Research* 2018; **310**: 261-9.
- 3 Painter SL, Hildebrand GD. Review of topical beta blockers as treatment for infantile hemangiomas. *Survey of Ophthalmology* 2016; **61**: 51-8.

- 4 Painter SL, Hildebrand GD. Topical timolol maleate 0.5% solution for the management of  
deep periocular infantile hemangiomas. *J aapos* 2016; **20**: 172-4.e1.
- 5 Semkova K, Kazandjieva J. Topical timolol maleate for treatment of infantile  
haemangiomas: preliminary results of a prospective study. *Clinical and Experimental  
Dermatology* 2013; **38**: 143-6.
- 6 DeMaria LN, Silverman NK, Shinder R. Ophthalmic Pyogenic Granulomas Treated With  
Topical Timolol-Clinical Features of 17 Cases. *Ophthalmic Plast Reconstr Surg* 2018; **34**:  
579-82.
- 7 Gupta D, Singh N, Thappa DM. Is timolol an effective treatment for pyogenic granuloma?  
*Int J Dermatol* 2016; **55**: 592-5.
- 8 Espadafor-López B, Cuenca-Barrales C, Salvador-Rodriguez L, Ruiz-Villaverde R.  
Iatrogenic Kaposi's Sarcoma Successfully Treated with Topical Timolol. *Actas  
Dermosifiliogr (Engl Ed)* 2020; **111**: 176-8.
- 9 Meseguer-Yebra C, Cardeñoso-Álvarez ME, Bordel-Gómez MT, Fraile-Alonso MC, Pérez-  
Losada ME, Sánchez-Estella J. Successful treatment of classic Kaposi sarcoma with  
topical timolol: report of two cases. *British Journal of Dermatology* 2015; **173**: 860-2.
- 10 Abdelmaksoud A, Filoni A, Giudice G, Vestita M. Classic and HIV-related Kaposi sarcoma  
treated with 0.1% topical timolol gel. *Journal of the American Academy of Dermatology*  
2017; **76**: 153-5.
- 11 Cahn BA, Kaur R, Hirt PA, Tchanque-Fossuo C, Dahle SE, Kirsner RS, Isseroff RR, Lev-  
Tov H. Use of Topical Timolol Maleate as Re-Epithelialization Agent for Treatment of  
Recalcitrant Wounds of Varying Etiologies. *J Drugs Dermatol* 2020; **19**: 1252-6.
- 12 Thomas B, Kurien JS, Jose T, Ulahannan SE, Varghese SA. Topical timolol promotes  
healing of chronic leg ulcer. *J Vasc Surg Venous Lymphat Disord* 2017; **5**: 844-50.
- 13 Chiaverini C, Passeron T, Lacour J-P. Topical timolol for chronic wounds in patients with  
junctional epidermolysis bullosa. *Journal of the American Academy of Dermatology* 2016;  
**75**: e223-e4.
- 14 Waldman RA, Lin G, Sloan B. Clinical pearl: topical timolol for refractory hypergranulation.  
*Cutis* 2019; **104**: 118-9.
- 15 Dabiri G, Tiger J, Goreshi R, Fischer A, Iwamoto S. Topical timolol may improve overall  
scar cosmesis in acute surgical wounds. *Cutis* 2017; **100**: E27-e8.
- 16 Beroukhim K, Rotunda AM. Topical 0.5% timolol heals a recalcitrant irradiated surgical  
scalp wound. *Dermatol Surg* 2014; **40**: 924-6.
- 17 Tang JC, Dosal J, Kirsner RS. Topical timolol for a refractory wound. *Dermatol Surg* 2012;  
**38**: 135-8.

- 18 Kimwattananukul K, Noppakun N, Asawanonda P, Kumtornrut C. Topical 0.5% Timolol Maleate Significantly Enhances Skin-Barrier Restoration After Fractional Carbon Dioxide Laser Treatment for Acne Scars. *Lasers Surg Med* 2021; **53**: 610-5.
- 19 Al Mokadem SM, Ibrahim AM, El Sayed AM. Efficacy of Topical Timolol 0.5% in the Treatment of Acne and Rosacea: A Multicentric Study. *J Clin Aesthet Dermatol* 2020; **13**: 22-7.
- 20 Tsai J, Chien AL, Kim N, Rachidi S, Connolly BM, Lim H, Alessi César SS, Kang S, Garza LA. Topical timolol 0.5% gel-forming solution for erythema in rosacea: A quantitative, split-face, randomized, and rater-masked pilot clinical trial. *J Am Acad Dermatol* 2021.
- 21 Afra TP, Razmi TM, De D. Topical timolol for postacne erythema. *J Am Acad Dermatol* 2021; **84**: e255-e6.
- 22 Pawar M. Topical timolol in chronic, recalcitrant fissures and erosions of hand eczema. *J Am Acad Dermatol* 2021; **84**: e125-e6.
- 23 Pyle TM, Heymann WR. Managing red scrotum syndrome (RSS) with topical timolol. *Int J Dermatol* 2019; **58**: e162-e3.
- 24 Pawar MK. Treatment of painful and deep fissures of the heel with topical timolol. *J Am Acad Dermatol* 2021; **85**: e3-e4.
- 25 Bhatia R, Hazarika N, Chandrasekaran D, Gupta V, Durgapal P, Kishore S. Treatment of Posttraumatic Reactive Angioendotheliomatosis With Topical Timolol Maleate. *JAMA Dermatology* 2021; **157**: 1002-4.
- 26 Behera B, Remya R, Chandrashekar L, Thappa DM, Gochhait D. Tufted angioma successfully treated with topical timolol gel-forming solution. *Indian J Dermatol Venereol Leprol* 2021; **87**: 581-4.
- 27 Shiuey Y, Eisenberg MJ. Cardiovascular effects of commonly used ophthalmic medications. *Clin Cardiol* 1996; **19**: 5-8.
- 28 Chen L, Tsai TF. The role of  $\beta$ -blockers in dermatological treatment: a review. *J Eur Acad Dermatol Venereol* 2018; **32**: 363-71.
- 29 Lin Z, Zhang B, Yu Z, Li H. The effectiveness and safety of topical  $\beta$ -receptor blocker in treating superficial infantile haemangiomas: A meta-analysis including 20 studies. *British Journal of Clinical Pharmacology* 2020; **86**: 199-209.
- 30 Sacchelli L, Vincenzi C, La Placa M, Piraccini BM, Neri I. Allergic contact dermatitis caused by timolol eyedrop application for infantile haemangioma. *Contact Dermatitis* 2019; **80**: 255-6.
- 31 Tawfik AA, Alsharnoubi J. Topical timolol solution versus laser in treatment of infantile hemangioma: a comparative study. *Pediatr Dermatol* 2015; **32**: 369-76.

Table 1 Uses of Topical Timolol in dermatology

Indications & references	Study design	Number of patients, <i>n</i>	Treatment period	Dose & frequency	Outcomes & adverse effects
Infantile hemangiomas Zheng L & Li Y, 2018 <sup>2</sup>	Meta-analysis including 10 studies. 5 randomized controlled trials, 3 prospective cohort studies and 2 retrospective cohort studies. The studies indicated moderate and high quality with moderate and acceptable bias risk.	887 infants with hemangioma. 603 with timolol group and 284 with the control group. 843 infants with superficial lesion; 40 infants with mixed lesion; 4 infants with deep lesion	varies from 2 to 6 months	9 studies used 0.5% timolol. Timolol was prescribed twice daily in 5 studies	Confirmed timolol monotherapy was superior on response rate and AE to placebo, observation and laser, yet when compared to propranolol there was no significant difference in the response rate.  RRs with 95% confidence intervals. A random effect model was utilized. 8 trials compared the response rate of timolol to laser, observation, placebo or propranolol with statistically significant heterogeneity ( $P < 0.00001$ , $I^2 = 83\%$ ) and significant response rate (RR = 2.86, 95% CI 1.31–6.24) when compared to controls, but no significant difference when compared to propranolol (RR = 0.99, 95% CI 0.70–1.42).  9 trials reported adverse effects when comparing timolol to the controls with statistically difference in adverse effects (RR = 0.21, 95% CI 0.05–0.97) and insignificant heterogeneity ( $P = 0.27$ , $I^2 = 23\%$ ).
Painter SL & Hildebrand GD, 2016 <sup>4</sup>	Retrospective and consecutive case series.	5 children with deep and periocular IH causing astigmatism, ptosis or change in head posture.	Timolol was used until full regression occurs.	Timolol maleate 0.5% solution. 3 drops rubbed by the parent twice every day until	All the affected children had regression in the lesion and improvement in the amblyogenic risk factors during the first 2 weeks. Timolol was continued until full regression occurred. Measurements and examinations were subjective.

Semkova K & Kazandjieva J, 2013 <sup>5</sup>	Prospective study	25 patients; 15 girls and 10 boys had 39 nonulcerated superficial localized Hs.	6 months	Timolol 0.1% gel. One drop of the gel per cm <sup>2</sup> five times daily.	<p>Ranges from 6 to 18 months. Ten months mean duration.</p> <p>lesion has regressed fully.</p> <p>Patients after cessation, had at least 8-month period of follow up in case a rebound occurred.</p> <p>In all cases no side effects were noted, but only one case had a mild wheeze due to a mistake in timolol application into the eye.</p> <p>Treatment efficacy evaluation was carried out at 4-week intervals via two separate investigators and concordance between them was calculated using the intraclass correlation coefficient (ICC).</p> <p>After the first 4 weeks, the consistency of all lesions moved from tense to soft.</p> <p>All IHs showed improvement giving a mean score of 2.56 (range 1.67-3) and the mean percentage change from baseline is 85% (range 55.6-100%). ICC for inter-rater. Reliability was 0.81. Complete clearance was noted in 3 children with plaque hemangiomas during the early phase of proliferation and also one child during the involuting phase. Timolol application during the proliferation phase was found superior to the involution phase giving a mean GAS of 2.61 (87%) and 2.21 (73.7%), respectively.</p> <p>No adverse effects were noted. No fluctuations in the vital signs were noted for the children with larger or multiple lesions who had higher quantities of the drug.</p>
--	-------------------	---	----------	--	--

**PYOGENIC GRANULOMA  
(PG)**

**DEMARIA LN ET AL., 2018<sup>6</sup>**

Retrospective interventional case series. 17 ocular PGs patients; 9 females and 8 males. Seven of the patients were children; less than 18 years. 6 weeks the whole study. Mean treatment duration for a complete resolution is 3.07 weeks (range from 2-5 weeks). Timolol 0.5% solution. Applied twice daily. Mean lesion size before treatment was 5.06×6.06mm. 13 patients had sessile (76%) and 4 patients presented with pedunculated lesions (24%). Fifteen patients showed a complete lesion resolution for a mean treatment duration of 3.07 weeks (range, 2-5 weeks) with no recurrences in a mean follow period of 9.47 months (range, 6-27 months).

Two patients had surgical excision after failing to present a response in a 6-week period. The cases had palpebral conjunctiva PG related to chalazion larger considerably than the other cases with the largest dimension of 18mm for both cases.

No side effects were noted.

**Gupta D et al., 2016<sup>7</sup>**

Case series 10 patients 4 months. A complete resolution occurred in 4 patients within 3-24 days. At the end of 3 months 5 patients had electrosurgery and one patient at the end of 6 Timolol 0.5% ophthalmic solution. Applied 4 times, daily in 2 drops per dose (0.05ml or 0.25 mg per drop). The efficacy of the treatment was determined by considering a complete response when the whole lesion disappears, a partial response when reduction in lesions number and/or size occur and no response when no reduction is noted. Four patients experienced a complete response during 3-24 days and no recurrence noted within 3 months of follow up. Three patients each presented with no response or partial response. Then, electrosurgery was performed to remove the lesions in five patients at the end of 3 months and one



			months.		patient had electrosurgery at the end of 6 months.
Kaposi's sarcoma (KS) - HIV negative	Case series	2 patients	12 weeks	0.5% timolol maleate solution.	No adverse effects were noted. No abnormality reported in blood pressure, blood glucose, ECG and heart rate.
Meseguer-Yebra C <i>et al.</i> , 2015 <sup>9</sup>				Applied twice daily, 1 or 2 drops for every lesion with gentle massage and no occlusion.	Both patients had follow up visits at 0, 2, 6 and 12 weeks.  Case 1 for a 78-year-old man showed significant changes after 2 weeks of treatment and the lesion changed to flattened and crusty lesion, and at 6 weeks of treatment the lesion remained as a smaller erythematous macule. At the end of the 12 weeks, lesion was excised and no evidence of KS was detected using HHV-8 immunohistochemical stain. No reoccurrence after 22 months of follow-up.  Case 2 for a 94-year-old female showed reduction in size and the crusty appearance appeared during the first weeks of treatment and at the 12 <sup>th</sup> week all 3 lesions presented as erythematous macules. Twenty months of follow up showed no recurrence.
Kaposi's sarcoma (KS) - HIV positive	Case series	4 patients. 3 cases with classic KS, and 1 case with HIV positive KS.	The 3 classic KS cases showed full resolution of the lesions in 4 to 5 weeks.	0.1% timolol gel. Twice daily administration until lesion is resolved.  In the HIV positive case, timolol was withdrawn as a	No side effects were noted for both cases.  The 3* cases of classic KS showed complete lesion resolution and disappearance of edema and pain within 4-5 weeks and no side effects for 6-10 months of follow up.  HIV positive case improved significantly by the end
Abdelmaksoud A <i>et al.</i> , 2017 <sup>10</sup>					

Chronic recalcitrant wound healing – (venous insufficiency, vasculitis, pressure sores, trauma)	Multi-center retrospective case-series study	39 patients; 32 males and 7 females with various chronic wounds etiologies including: venous leg ulcers, traumatic wounds, pyoderma gangrenosum, diabetic foot ulcer, malignancy (non-HIV KS), radiation dermatitis, post-surgical, post-surgical and radiation, Graft versus host disease, Neuropathic truma, pressure, vasculitis,	The HIV positive case continued timolol treatment to 6 weeks only.  Healed group: 89.5 days median treatment duration.  Decreasing wound area group: 122 days median treatment duration. 8 were still receiving treatment at the	precautionary procedure.  0.5% timolol maleate applied for at least 4 weeks.  Timolol with used in addition to standard of care therapy.  1 drop per cm <sup>2</sup> of wound area instilled with dressing. Dressing changes occur twice daily, once daily or every other day. Some	of the 6 <sup>th</sup> week. During the 5 <sup>th</sup> week of treatment, patient experienced asthenia, unexplained fever, and failure to systematic antibiotic response. The patient was positive for tuberculosis and HIV with 360 cells/mm <sup>3</sup> CD4 cell count. Timolol was withdrawn and patient started emtricitabine/tenofovir disoproxil fumarate combination in addition to efavirenz once daily by the end 8 <sup>th</sup> week. No signs recurrence or spreading were noted during the 4 months follow up. The highly active antiretroviral therapy might have contributed to the maintenance of lesion remission, timolol 0.1% gel was the only drug used in the first 6 weeks supporting the therapeutic efficacy of timolol.  *1 patient was having oral bisoprolol 10mg/d during the treatment course.  Authors reported healing criteria as: healing when complete re-epithelialization of the wound and closure occur, improved when wound size decreases and worsening when wound size area increases.  34 wounds healed, 15 wounds decreased in wound area and 2 venous leg ulcers increased their wound area. 4 wounds remained unchanged.  healed group: median healing rate was - 0.25cm <sup>2</sup> /week. Most of the wounds had timolol
---	--	--	--	---	---

Cahn BA *et al.*, 2020<sup>11</sup>

bullous pemphigoid,  
compulsive skin picking.

time of analysis.

patients had continuous  
application by a delivery  
system.

applied daily. 3 out of 34 healed wounds had  
wounds occurring a location different than the leg (1  
diabetic foot ulcer, 1 abdominal post-surgical  
wound). Etiologies are mainly venous leg ulcers  
and traumatic wounds.

Increasing wound  
area group:  
157 days  
median treatment  
duration.

Decreasing wound area group: median healing rate  
was  $-0.24\text{cm}^2/\text{week}$ . Median wound size decreased  
by 62%. Majority of the wounds occurred on the leg  
( $n=11$ ), but 4 occurred in different locations for  
example the scalp, abdomen, and foot. The major  
etiology in this subgroup include venous leg ulcer.

No change in  
wound area  
group: 76 days  
median treatment  
duration.

Increasing wound area group: median rate of  
wound area increase was  $0.17\text{cm}^2/\text{week}$ . Median  
percentage increase in wound area was 193%. All  
etiologies were venous leg ulcers.

No change in wound area group: Four wounds  
remained unchanged including traumatic, radiation  
dermatitis, bullous pemphigoid and compulsive skin  
picking (difficult to evaluate due to self-  
excoriations).

No adverse effects were reported due to timolol  
usage.

Chronic diabetic and venous  
ulcers

case-control study.  
prospective and  
nonrandomized  
single-center

60 patients with chronic leg  
ulcers due to venous  
insufficiency or diabetes of  
less than 6 weeks in

12 weeks

0.5% timolol maleate, one  
drop applied for each 2 cm  
of the wound perimeter  
every day in addition to the

At 0, 4, 8 and 12 weeks, the ulcer area was  
calculated via plotting ulcer perimeter on graph  
paper and the area was measured manually. The  
change in ulcer area in percentage was used to

Thomas B *et al.*, 2017<sup>12</sup>

study.	duration.	conventional therapy (antibiotics, glyceamic control, absorbent dressing every 2 days unless it was heavily soaked, devitalized tissue débridement if required). Timolol was dried before dressing placement.	<p>assess the healing rate at 4, 8 and 12 weeks.</p> <p>Timolol group had 24.04, 27.39, and 40.76 mean percentage change in ulcer area at 4, 8, and 12 weeks, while the control had 12.98, 14.58, and 16.52. The healing rate with timolol group is better and there is a statistically significant difference P value &lt; 0.05 including all the three means.</p> <p>Timolol group had 25.29, 43.77, and 61.79 percentage change of the ulcer area at 4, 8, and 12 weeks, while the control had 1.92, 22.40, and 29.62. Repeated-measures mixed analysis of variance was used and indicated that across the three time points was significant difference <math>F(1.25,72.56) = 94.49</math> (<math>P &lt; .001</math>), and the study group and the control group in the ulcer area percentage change had significant differences <math>F(1,58) = 14.41</math> (<math>P &lt; .001</math>)</p> <p>Only 1 venous insufficiency patient and 3 diabetic patients in the timolol group had a complete healing at the end of study period (12 weeks). No full healing in control group. No ulcer recurrences were noted for study period.</p> <p>No significant difference was revealed by the study in the rate of healing between nonsmokers and smokers or alcohol consumption. In the timolol</p>
--------	-----------	---	---

<p>Junctional epidermolysis bullosa (JEB) Chiaverini C <i>et al.</i>, 2016<sup>13</sup></p>	<p>Case series</p>	<p>2 patients; both are 1 year old patients with generalized intermediate JEB subtype. Patient 1 had nail bed chronic wound and patient 2 had neck fold chronic wounds.</p>	<p>Patient 1 with nail bed chronic wounds had 3 weeks treatment course.  Patient 2 with neck fold chronic wounds had 8 weeks treatment</p>	<p>Topical timolol 0.5%.  Twice daily application 2-3 LP eye drops with occlusion.</p>	<p>group, no difference in healing rate was noted by gender.</p> <p>The healing rate for chronic diabetic ulcer patients and chronic venous patient in both the study and control groups was not different significantly.</p> <p>No major adverse effects were reported. Only three patients mentioned itchiness around the ulcers occasionally.</p> <p>Patient 1 with nail bed chronic wound had 3 weeks of 2 drops timolol therapy and obtained 100% healing.</p> <p>Patients 2 with neck fold chronic wound had 8 weeks of timolol therapy and obtained 80% healing.</p> <p>Parents reported no adverse effects.</p>
<p>Refractory Hypergranulation Waldman RA <i>et al.</i>, 2019<sup>14</sup></p>	<p>Case series</p>	<p>2 patients</p>	<p>Up to 14 days (patient 1) or until complete resolution occurs (9 days for patient 2)</p>	<p>Timolol maleate ophthalmic gel forming solution 0.5% twice daily in addition to normal routine wound care and daily dressing changes.</p>	<p>Patient 1: Resolution of hypergranulation and surgical sites re-epithelialization with 2 weeks of timolol therapy after 6 weeks refractory hyperregulation to routine wound care and topical silver nitrate.</p> <p>Patient 2: Resolution of hypergranulation and surgical sites re-epithelialization with 9 days of timolol therapy after several months a traumatic injury refractory hyperregulation to topical and oral</p>

<p>Overall scar cosmesis in acute surgical wounds</p> <p>Dabiri G <i>et al.</i>, 2017<sup>15</sup></p>	<p>Randomized controlled trial (RCT)</p>	<p>9 enrolled in the study but 6 completed the study. 3 patients in the study group and 3 in the control.</p>	<p>13 weeks or less if healed earlier.</p>	<p>Not mentioned?!</p> <p>Timolol (maybe ophthalmic solution). Dose is not mentioned.</p> <p>Timolol is applied and then 40 mm Hg compression stockings were worn.</p>	<p>antibiotics and nonadherent sterile gauze dressings every day.</p> <p>No adverse effects were noted that require discontinuation of timolol therapy.</p> <p>The authors defined the healed wound as a wound without exudate, and with complete reepithelialization and stability for 1 week. (VAS) visual analog scale is the subjective scar assessment used to calculate scar cosmesis.</p> <p>2×2 cm was the average wound size with a depth of 1mm.</p> <p>The VAS was measured by outside blinded dermatologist and results showed timolol treated wounds had more cosmetically favorable scars compared to the control (mean [SD]: 6.5 [0.9] vs 2.5 [0.7]; P&lt;.05).</p> <p>The paper didn't mention adverse effects.</p>
<p>Recalcitrant irradiated surgical (Mohs surgery) scalp wound</p> <p>Beroukhim K &amp; Rotunda AM, 2014<sup>16</sup></p>	<p>Case report</p>	<p>1 patient</p>	<p>4 months</p>	<p>3 to 4 drops of 0.5% topical timolol maleate distributed to the entire wound twice daily, but then reduced to once daily, every other, or every third day due to mild irritant dermatitis.</p>	<p>Patient's surgical defect following 2 stages of Mohs surgery was 10 × 11 cm with uncovered bone pitting. Patient initially followed wound care routine consisting of soap and water washing of the scalp daily or every other day and using petroleum jelly and a nonadherent bandage to cover the wound. After 3 years of routine wound care, modest improvement with poor vascularized and friable</p>

					Timoptic ophthalmic solution.	granulation tissue persistence over central zone of the pitted bone.  The Recalcitrant irradiated surgical (Mohs surgery) scalp wound had a flattening of the granulation tissue and nearly complete reepithelialization after 2 months of timolol therapy and wound care (consists of soap and water washing of the scalp daily or every other day and using petroleum jelly and a nonadherent bandage to cover the wound). After 4 months of timolol therapy and wound routine, a complete reepithelialization of the entire wound was noted.  Adverse effects: mild contact dermatitis, mild erythema.
Refractory chronic mid-back wound  Tang JC <i>et al.</i> , 2012 <sup>17</sup>	Case report	1 patient with large refractory wound on her left mid-back	8 weeks	3 to 4 drops of every day of topical timolol drops 0.5% to the wounds and the wound were covered via a soft silicon dressing.	A complete and rapid epithelization for the 43-year-old women had refractory a 26-cm <sup>2</sup> defect with 3.5 cm depth thoracic back wound with an underlying 6- × 9 4-cm ulcer with red-pink granulation tissue.	No significant adverse effects were noted and treatment was well tolerated.
Fractional CO <sub>2</sub> laser therapy (AFCO <sub>2</sub> )  Kimwattananukul K <i>et al.</i> , 2021 <sup>18</sup>	Split-face double blind and randomized placebo-controlled trial	25 patients with history of atrophic scars for at least 3 months. Mean age (SD) is 31.4 (5.2) years. Fitzpatrick skin phototype IV constitutes 80% of the	7 consecutive days	10-15 drops of 0.5% topical applied twice daily immediately after the laser procedure. A moisturizer and sunscreen were also used.	Follow up visits includes 48, 96 and 168 hours post Fractional CO <sub>2</sub> laser therapy. All 25 patients completed the study.	Patients' adherence was evaluated via measuring solution bottles at baseline and at end of the study.

participants' skin.

There was no significant difference in timolol and normal saline quantities during the study period (4.14 vs. 4.25 g, respectively;  $P = 0.26$ ).

After 48 hours of post-AFCO<sub>2</sub> therapy until the end of study, timolol treated side had significantly higher skin hydration level compared to normal saline treated side ( $P < 0.001$ ). TEWL (transepidermal water loss) levels were significantly lower at timolol treated side compared to the controls for every follow-up visit  $P < 0.001$ .

Colorimetry measurement showed no significant difference in skin erythema reduction between timolol and control group at all time points.

No difference seen in timolol and control group regarding erythema and edema scores at 48, 96, and 168 hours after the AFCO<sub>2</sub> treatment.

96 hours post-AFCO<sub>2</sub> therapy, crusting score on showed a significant greater improvement in timolol treated side (crusting scores: 1, 19/25 [76%] and 2, 6/25 [24%]) compared to the controls (crusting scores: 1, 9/25 [36%] and 2, 16/25 [64%]) ( $P = 0.002$ ). Photographs were consistent with crusting scores and indicated visually the reduction in crusting in the timolol treated cheeks throughout the study period.



Acne and rosacea	Multicentric study (case series, I think?)	166 patients; 58 patients with rosacea (erythematotelangiectatic or papulopustular Rosacea) and 58 with acne (mild or moderate acne) patients.	8 weeks	4 to 8 drops of 0.5% topical timolol maleate applied every night.	<p>At 48h and 168h post-AFCO<sub>2</sub> treatment, timolol treated side demonstrated slightly lower pruritus and tightness scores compared to controls, yet the differences were not statistically significant.</p> <p>No adverse effects were reported from the patients during the study period. Six patients had mild and transient post-inflammatory hyperpigmentation in both cheeks (timolol treated cheek and control cheek)</p> <p>For acne the global acne grading system was used. Investigator's Global Assessment (IGA) score and a rosacea clinical scale were used for rosacea.</p> <p>Acne group included 42 (72.4%) mild acnes and 16 (27.6%) moderate acne. After therapy, a high statistical significant decrease in papules, TLC (total lesion count), ASI (acne severity index), comedones from the baseline and pustules showed statistical significant reduction also. The means percentage improvement were 28.17% comedones, 26.81% papules, 16.05% pustules, 25.11% TLC and 23.24% ASI.</p> <p>Rosacea group included 10 (17.2%) mild cases, 32 (55.2%) moderate cases and 16 (27.6%) severe cases according to IGA. After therapy, 10.4% of patients demonstrated "clear" or almost clear score IGA. After therapy, 20.6% of the cases were considered severe, 34.5% moderate cases and</p>
------------------	--	--	---------	---	--

Erythematotelangiectatic  
rosacea

Tsai J *et al.*, 2021<sup>20</sup>

A quantitative,  
split-face,  
randomized, and  
rater-masked pilot  
clinical trial

8 patients with rosacea  
containing flushing and  
persistent erythema.

16 weeks of  
timolol treatment  
for one side of the  
face. The  
contralateral side  
received no  
treatment for the  
first 8 weeks and  
then treated the  
following 8 weeks.

0.5% topical timolol gel-  
forming solution applied  
twice daily.

34.5% mild cases compared to (27.6%, 55.2% and 17.2%, respectively) according to IGA. 55.1% of patients were considered as non-responders per IGA results.

Adverse effects for both groups were mild and tolerable. Most reported adverse effect was dryness. Adverse effects also include a burning sensation, mild irritation, scaly skin, itching, stinging and erythema.

Facial erythema was measured using tristimulus colorimetry and computer-aided image analysis (CAIA) of cross-polarized photographs from baseline and then every 4 weeks until 4 weeks after treatment stoppage. Patients asked to rate flushing from 1 "much worse" to 5 "much better" for each photobaseline visit.

Four patients reported improvement with treatment. Three patients reported worsened flushing after therapy discontinuation.

There is a strong correlation between colorimeter and CAIA-measured facial erythema ( $r = 0.71$ ,  $P < .001$ )

With the mixed-effects models, erythema decreased in both sides of the face (treated and untreated) during the early 8 weeks yet considered

<b>POST-ACNE ERYTHEMA AND HYPERPIGMENTATION</b>	Case report	One patient	12 weeks	0.5% topical timolol maleate ophthalmic solution applied at bedtime.	<p>insignificant statistically. Upon subsequent therapy for both sides, improvement was seen only in the longer treated side most significantly observed at 12<sup>th</sup> week (colorimeter-20.0%, adjusted <math>P= .001</math>; CAIA -20.9%, adjusted <math>P = .047</math>)</p> <p>Erythema recovered at week 16 suggesting tolerance. Erythema rebound was observed after timolol discontinuation.</p> <p>Only one adverse event was reported which is one episode of transient lower eyelid sensitivity.</p> <p>Significant improvement in post-inflammatory erythema of patient's acne leaving only shallow rolling scars and no pigmentation. Evaluation was made with dermoscopy.</p>
AFRA TP ET AL., 2021 <sup>21</sup>					
Eczema	Case report	One patient	1 week	0.5% ophthalmic timolol solution administered 2-3 drops on the fissure/erosion areas.	<p>No adverse effects were noted.</p> <p>A patient with chronic hand eczema demonstrated healed recalcitrant fissures and erosions after one week of timolol therapy.</p>
Pawar M, 2021 <sup>22</sup>					
Red scrotum syndrome	Case report	One patient	2 weeks	0.5% Topical timolol maleate gel forming solution applied twice daily.	<p>The paper didn't mention any adverse effects.</p> <p>A 48-year-old man with 2 months history of resistant red scrotum syndrome to fluconazole 200 mg, minocycline, topical nystatin-triamcinolone acetonide cream, tacrolimus 0.1% ointment and topical mupirocin 2% ointment.</p> <p>The patient had a trial of 6.25 mg carvedilol daily</p>
Pyle TM & Heymann WR, 2019 <sup>23</sup>					

Deep painful heel fissures  Pawar MK, 2021 <sup>24</sup>	Case report	One patient	4 weeks	2 to 3 drops of 0.5% ophthalmic timolol solution applied over the fissures at bedtime.	but without improvement. Timolol was added and the erythema and symptom resolved rapidly within 2 weeks. The patient continued carvedilol due to hypertension and symptoms of RSS returned when timolol was withdrawn. The symptoms resolved after timolol therapy restarted.  The paper didn't mention adverse effects. After 2 weeks of timolol therapy and wearing good fitting and closed-back shoes, symptoms resolved and healed significantly. Therapy continued for another 2 weeks and no recurrence of heel fissures were noted after 4 weeks of treatment.
Posttraumatic reactive angioendotheliomatosis  Bhatia R <i>et al.</i> , 2021 <sup>25</sup>	Case report	One patient; male patient in his 20s	6 weeks	2 drops of timolol maleate 0.5% ophthalmic solution applied 3 times daily	The paper didn't mention adverse effects. A complete resolution for all 7 Reactive angioendotheliomatosis (RAE) lesions with mild scarring. No lesions reoccurrence after 1 year of follow up.
<b>TUFTED ANGIOMA</b>  <b>BEHERA B ET AL., 2021<sup>25</sup></b>	Case report	One patient; a four-month-old male.	6 months	0.5% gel-forming solution applied thrice daily and then reduced to twice daily, once daily and then stopped.	The paper didn't mention any adverse effects. After 4 months of timolol therapy, almost a complete resolution occurred to 6 cm × 3cm circumferential unusual reddish-brown horseshoe-shaped plaque tufted angioma. Treatment dosage was reduced and then stopped over the following 2 months. No lesion recurrence after one year of treatment stoppage.

No complain of adverse effects were reported by the parents.